Lung stereotactic radiotherapy for oligometastases: Comparison of oligo-recurrence and sync-oligometastases

Hideomi Yamashita, Yuzuru Niibe, Takaya Yamamoto, Kuniaki Katsui, Keiichi Jingu, Susumu Kanazawa, Atsuro Terahara, Keiichi Nakagawa

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Oligometastases can be divided into sync-oligometastases and oligo-recurrence. The difference is whether the primary site is uncontrolled or controlled. The goal of this multicenter study was to evaluate treatment outcomes and factors affecting survival after stereotactic body radiotherapy for pulmonary oligometastases. Methods: The information after stereotactic body radiotherapy from January 2004 to April 2014 was retrospectively collected. Ninety-six patients (65 males, 31 females) were enrolled. Ten cases (10%) were sync-oligometastases, 79 cases (82%) were oligo-recurrences and 7 (7%) were unclassified oligometastases with < 6 months of disease-free interval. The median disease-free interval between initial therapy and stereotactic body radiotherapy was 24 months. The median calculated biological effective dose was 105.6 Gy. Results: The median follow-up period was 32 months for survivors. The 3-year overall survival and relapse-free survival rates were 53% and 32%, respectively. No Grade 5 toxicity occurred. The median overall survival was 23.9 months for sync-oligometastases and 66.6 months for oligo-recurrence (P = 0.0029). On multivariate analysis, sync-oligometastases and multiple oligometastatic tumors were significant unfavorable factors for both overall survival and relapse-free survival. Conclusions: In stereotactic body radiotherapy for oligometastatic lung tumors, the state of oligorecurrence has the potential of a significant prognostic factor for survival.

Original languageEnglish
Pages (from-to)687-691
Number of pages5
JournalJapanese Journal of Clinical Oncology
Volume46
Issue number7
DOIs
Publication statusPublished - 2016

Fingerprint

Radiotherapy
Radiosurgery
Recurrence
Lung
Survival
Multicenter Studies
Survivors
Neoplasms
Multivariate Analysis
Survival Rate
Therapeutics

Keywords

  • Oligo-recurrence
  • Pulmonary oligometastases
  • SBRT
  • Sync-oligometastases

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Lung stereotactic radiotherapy for oligometastases : Comparison of oligo-recurrence and sync-oligometastases. / Yamashita, Hideomi; Niibe, Yuzuru; Yamamoto, Takaya; Katsui, Kuniaki; Jingu, Keiichi; Kanazawa, Susumu; Terahara, Atsuro; Nakagawa, Keiichi.

In: Japanese Journal of Clinical Oncology, Vol. 46, No. 7, 2016, p. 687-691.

Research output: Contribution to journalArticle

Yamashita, Hideomi ; Niibe, Yuzuru ; Yamamoto, Takaya ; Katsui, Kuniaki ; Jingu, Keiichi ; Kanazawa, Susumu ; Terahara, Atsuro ; Nakagawa, Keiichi. / Lung stereotactic radiotherapy for oligometastases : Comparison of oligo-recurrence and sync-oligometastases. In: Japanese Journal of Clinical Oncology. 2016 ; Vol. 46, No. 7. pp. 687-691.
@article{5e8fe722244447b5ab291e71aec7c9ed,
title = "Lung stereotactic radiotherapy for oligometastases: Comparison of oligo-recurrence and sync-oligometastases",
abstract = "Background: Oligometastases can be divided into sync-oligometastases and oligo-recurrence. The difference is whether the primary site is uncontrolled or controlled. The goal of this multicenter study was to evaluate treatment outcomes and factors affecting survival after stereotactic body radiotherapy for pulmonary oligometastases. Methods: The information after stereotactic body radiotherapy from January 2004 to April 2014 was retrospectively collected. Ninety-six patients (65 males, 31 females) were enrolled. Ten cases (10{\%}) were sync-oligometastases, 79 cases (82{\%}) were oligo-recurrences and 7 (7{\%}) were unclassified oligometastases with < 6 months of disease-free interval. The median disease-free interval between initial therapy and stereotactic body radiotherapy was 24 months. The median calculated biological effective dose was 105.6 Gy. Results: The median follow-up period was 32 months for survivors. The 3-year overall survival and relapse-free survival rates were 53{\%} and 32{\%}, respectively. No Grade 5 toxicity occurred. The median overall survival was 23.9 months for sync-oligometastases and 66.6 months for oligo-recurrence (P = 0.0029). On multivariate analysis, sync-oligometastases and multiple oligometastatic tumors were significant unfavorable factors for both overall survival and relapse-free survival. Conclusions: In stereotactic body radiotherapy for oligometastatic lung tumors, the state of oligorecurrence has the potential of a significant prognostic factor for survival.",
keywords = "Oligo-recurrence, Pulmonary oligometastases, SBRT, Sync-oligometastases",
author = "Hideomi Yamashita and Yuzuru Niibe and Takaya Yamamoto and Kuniaki Katsui and Keiichi Jingu and Susumu Kanazawa and Atsuro Terahara and Keiichi Nakagawa",
year = "2016",
doi = "10.1093/jjco/hyw047",
language = "English",
volume = "46",
pages = "687--691",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Lung stereotactic radiotherapy for oligometastases

T2 - Comparison of oligo-recurrence and sync-oligometastases

AU - Yamashita, Hideomi

AU - Niibe, Yuzuru

AU - Yamamoto, Takaya

AU - Katsui, Kuniaki

AU - Jingu, Keiichi

AU - Kanazawa, Susumu

AU - Terahara, Atsuro

AU - Nakagawa, Keiichi

PY - 2016

Y1 - 2016

N2 - Background: Oligometastases can be divided into sync-oligometastases and oligo-recurrence. The difference is whether the primary site is uncontrolled or controlled. The goal of this multicenter study was to evaluate treatment outcomes and factors affecting survival after stereotactic body radiotherapy for pulmonary oligometastases. Methods: The information after stereotactic body radiotherapy from January 2004 to April 2014 was retrospectively collected. Ninety-six patients (65 males, 31 females) were enrolled. Ten cases (10%) were sync-oligometastases, 79 cases (82%) were oligo-recurrences and 7 (7%) were unclassified oligometastases with < 6 months of disease-free interval. The median disease-free interval between initial therapy and stereotactic body radiotherapy was 24 months. The median calculated biological effective dose was 105.6 Gy. Results: The median follow-up period was 32 months for survivors. The 3-year overall survival and relapse-free survival rates were 53% and 32%, respectively. No Grade 5 toxicity occurred. The median overall survival was 23.9 months for sync-oligometastases and 66.6 months for oligo-recurrence (P = 0.0029). On multivariate analysis, sync-oligometastases and multiple oligometastatic tumors were significant unfavorable factors for both overall survival and relapse-free survival. Conclusions: In stereotactic body radiotherapy for oligometastatic lung tumors, the state of oligorecurrence has the potential of a significant prognostic factor for survival.

AB - Background: Oligometastases can be divided into sync-oligometastases and oligo-recurrence. The difference is whether the primary site is uncontrolled or controlled. The goal of this multicenter study was to evaluate treatment outcomes and factors affecting survival after stereotactic body radiotherapy for pulmonary oligometastases. Methods: The information after stereotactic body radiotherapy from January 2004 to April 2014 was retrospectively collected. Ninety-six patients (65 males, 31 females) were enrolled. Ten cases (10%) were sync-oligometastases, 79 cases (82%) were oligo-recurrences and 7 (7%) were unclassified oligometastases with < 6 months of disease-free interval. The median disease-free interval between initial therapy and stereotactic body radiotherapy was 24 months. The median calculated biological effective dose was 105.6 Gy. Results: The median follow-up period was 32 months for survivors. The 3-year overall survival and relapse-free survival rates were 53% and 32%, respectively. No Grade 5 toxicity occurred. The median overall survival was 23.9 months for sync-oligometastases and 66.6 months for oligo-recurrence (P = 0.0029). On multivariate analysis, sync-oligometastases and multiple oligometastatic tumors were significant unfavorable factors for both overall survival and relapse-free survival. Conclusions: In stereotactic body radiotherapy for oligometastatic lung tumors, the state of oligorecurrence has the potential of a significant prognostic factor for survival.

KW - Oligo-recurrence

KW - Pulmonary oligometastases

KW - SBRT

KW - Sync-oligometastases

UR - http://www.scopus.com/inward/record.url?scp=84989232173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989232173&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyw047

DO - 10.1093/jjco/hyw047

M3 - Article

C2 - 27162324

AN - SCOPUS:84989232173

VL - 46

SP - 687

EP - 691

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 7

ER -